HCA
CTNM

Harbor Capital Advisors’s Contineum Therapeutics CTNM Stock Holding History

Harbor Capital Advisors’s Portfolio CTNM Stock Details CTNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-145
Closed -$1K – 1506
2025
Q2 		$1K Sell
145
-22
-13% -$96 ﹤0.01% 1379
2025
Q1 		$1K Buy
167
+1
+0.6% +$9 ﹤0.01% 1399
2024
Q4 		$2K Sell
166
-2
-1% -$32 ﹤0.01% 1297
2024
Q3 		$3K Buy
+168
New +$3.22K ﹤0.01% 1266

Other funds holding CTNM

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

Harbor Capital Advisors's CTNM Position: Q3 2025 in Review

Harbor Capital Advisors sold out of Contineum Therapeutics (CTNM) in Q3 2025, closing a stake of 145 shares — an estimated $1K sold.

Harbor Capital Advisors first reported a position in CTNM in Q3 2024 and held it in 4 quarters. The position peaked at $3K in Q3 2024. 62 funds tracked by Wall St. Rank hold CTNM as of Q3 2025.

  • Harbor Capital Advisors reported no remaining Contineum Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Harbor Capital Advisors sold 145 Contineum Therapeutics shares in Q3 2025, an estimated $1K.
  • Harbor Capital Advisors first reported a position in Contineum Therapeutics in Q3 2024 and held it in 4 quarters.
  • Harbor Capital Advisors's Contineum Therapeutics position peaked at $3K in Q3 2024.
  • 62 funds tracked by Wall St. Rank held Contineum Therapeutics as of Q3 2025.

Based on Harbor Capital Advisors's 13F filing for Q3 2025, filed 15 Oct 2025.